New Combination Therapy Could Reduce Ischaemia After Heart Attack (p 605)August 22, 2001Encouraging results from a fast-track study published in this week's issue of THE LANCET suggest a new therapeutic strategy for reducing ischaemic complications (coronary artery blockage) after heart attack. The treatment of acute heart attack requires combination of several therapies. Fibrinolytic agents given together with aspirin and unfractionated heparin often fail to restore coronary artery bloodflow. Frans Van de Werf and colleagues from Gasthuisberg University, Leuven, Belgium, did an exploratory trial to identify whether specific combinations with newer antithrombotic agents might provide clinical benefit. The aim of the study was to compare the efficacy and safety of three antithrombotic therapies with the fibrinolytic agent tenecteplase. 6095 patients (from 575 hospitals in 26 countries) with acute heart attack of less than six hours were randomly assigned one of three combinations: full-dose tenecteplase and enoxaparin (a low-molecular-weight heparin) for a maximum of 7 days (enoxaparin group); half-dose tenecteplase with weight-adjusted low-dose unfractionated heparin and a 12-hour infusion of abciximab ,a glycoprotein IIb/IIIa inhibitor of platelet aggregation,(abciximab group); or full-dose tenecteplase with weight-adjusted unfractionated heparin for 48 hours(unfractionated heparin reference group.) The primary endpoints were the composites of death within 30 days, recurrence of heart attack in hospital, or ischaemia in hospital. A further endpoint of intracranial bleeding or other bleeding complications was added to assess therapeutic safety. There were significantly fewer endpoints in the enoxaparin and abciximab groups than in the unfractionated heparin group (11.4% and 11.1% compared with 15.4%); Similar differences between groups were found when the combined efficacy plus safety outcome was assessed (13.7% and 14.2% compared with 17%) Frans Van de Werf comments: "The tenecteplase plus enoxaparin or abciximab regimens studied here reduce the frequency of ischaemic complications of an acute heart attack. Taking into account efficacy and safety, the combination of full-dose tenecteplase and prolonged subcutaneous administration of enoxaparin emerged as the best treatment in this trial. Because of additional advantages such as the ease of administration and the lack of need for monitoring of anticoagulation, this combination should be regarded as an attractive alternative pharmacological reperfusion strategy deserving further study." Lancet |
|||||||||||||||||||||
| Related Heart Attack Current Events and Heart Attack News Articles Fat around the middle increases the risk of dementia Women who store fat on their waist in middle age are more than twice as likely to develop dementia when they get older, reveals a new study from the Sahlgrenska Academy. Inhibition of GRK2 is protective against acute cardiac stress injuries Inhibition of a protein known to contribute to heart failure also appears to be protective of the heart in more acute cardiac stress injury, namely ischemia reperfusion. Vitamin B niacin offers no extra benefit to statin therapy in seniors already diagnosed with CAD The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. Heart and bone damage from low vitamin D tied to declines in sex hormones Researchers at Johns Hopkins are reporting what is believed to be the first conclusive evidence in men that the long-term ill effects of vitamin D deficiency are amplified by lower levels of the key sex hormone estrogen, but not testosterone. Elevated biomarkers lead to diminished quality of life in heart attack patients post-discharge Many heart attack patients have high levels of cardiac biomarkers in the blood for several months after leaving the hospital, with more shortness of breath and chest pain, according to a Henry Ford Hospital study. Tiny particles can deliver antioxidant enzyme to injured heart cells Researchers at Emory University and the Georgia Institute of Technology have developed microscopic polymer beads that can deliver an antioxidant enzyme made naturally by the body into the heart. Early end to key study on benefits of niacin, a B vitamin, in keeping arteries open was premature Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. oo much selenium can increase your cholesterol A new study from the University of Warwick has discovered taking too much of the essential mineral selenium in your diet can increase your cholesterol by almost 10%. Higher carotid arterial stenting rates associated with poorer clinical outcomes Among eligible Medicare beneficiaries, increased use of carotid arterial stenting (CAS) procedures to treat carotid stenosis-the narrowing of the carotid artery-is associated with higher rates of mortality and adverse clinical outcomes, including heart attack and stroke, according to researchers from the University of Pennsylvania School of Medicine. Study suggests dentists can identify patients at risk for fatal cardiovascular event A new study indicates dentists can play a potentially life-saving role in health care by identifying patients at risk of fatal heart attacks and referring them to physicians for further evaluation. More Heart Attack Current Events and Heart Attack News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||